Chronic cyclooxygenase blockade enhances the vasopressin responsiveness in collaterals of portal hypertensive rats

References

• Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985; 248: G618–25
   PubMed Web of Science ®Google Scholar
• Ranek L, Vilstrup H, Iversen J, Petersen P, Milandri M. The effect of continuous vasopressin infusion on splanchnic blood flow, liver function, and portal and central venous pressures in patients with cirrhosis. Scand J Clin Lab Invest 1984; 44: 251–6
   PubMed Web of Science ®Google Scholar
• Westaby D, Gimson A, Hayes PC, Williams R. Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension. Gut 1988; 29: 372–7
   PubMed Web of Science ®Google Scholar
• Merkel C, Gatta A, Bolognesi M, Finucci G, Battaglia G, Angeli P, et al. Hemodynamic changes of systemic, hepatic and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci 1988; 33: 1103–9
   PubMed Web of Science ®Google Scholar
• Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Chu CJ, et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999; 30: 630–5
   PubMed Web of Science ®Google Scholar
• Valla D, Geoffroy P, Girod C, Lebrec D. Circulatory actions of vasopressin in anaesthetized rats with portal hypertension subjected to haemorrhage. J Hepatol 1986; 2: 328–39
   PubMed Web of Science ®Google Scholar
• Kravetz D, Cummings SA, Groszmann RJ. Hyposensitivity to vasopressin in a hemorrhage-transfused rat model of portal hypertension. Gastroenterology 1987; 93: 170–5
   PubMedGoogle Scholar
• Valla D, Girod C, Lee SS, Braillon A, Lebrec D. Lack of vasopressin action on splanchnic hemodynamics during bleeding: a study in conscious, portal hypertensive rats. Hepatology 1988; 8: 10–5
   PubMedGoogle Scholar
• Tsai YT, Lee FY, Lin HC, Lee SD, Hsia HC, Lin WJ, et al. Hyposensitivity to vasopressin in patients with hepatitis B-related cirrhosis during acute variceal bleeding. Hepatology 1991; 13: 407–12
   PubMedGoogle Scholar
• Sitzmann JV, Li SS, Lin PW. Prostacyclin mediates splanchnic vascular response to norepinephrine in portal hypertension. J Surg Res 1989; 47: 208–11
   PubMedGoogle Scholar
• Wu Y, Li SS, Campbell KA, Sitzmann JV. Modulation of splanchnic vascular sensitivity to angiotensin II. Surgery 1991; 110: 162–8
   PubMed Web of Science ®Google Scholar
• Lipton HL, Chapnick BM, Hyman AL, Kadowitz PG. Inhibition of vasoconstrictor responses by prostacyclin (PGI2) in the feline mesenteric vascular bed. Arch Int Pharmacodyn Ther 1979; 241: 214–23
   PubMedGoogle Scholar
• Oberti F, Sogni P, Cailmail S, Moreau R, Pipy B, Lebrec D. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic and intrahepatic portal hypertension. Hepatology 1993; 18: 621–7
   PubMedGoogle Scholar
• Guarner C, Soriano G, Such J, Teixidó M, Ramis I, Bulbena O, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992; 102: 303–9
   PubMedGoogle Scholar
• Sitzmann JV, Campbell KA, Wu Y, Cameron JL. Effect of portosystemic shunting on PGI2 and glucagon levels in humans. Ann Surg 1993; 217: 248–52
   PubMed Web of Science ®Google Scholar
• Lee FY, Chu CJ, Wang SS, Chang FY, Lin HC, Hou MC, et al. Inhibition of prostacyclin by indomethacin ameliorates the splanchnic hyposensitivity to glypressin in haemorrhage-transfused common bile duct-ligated rats. Eur J Clin Invest 2001; 31: 145–53
   PubMedGoogle Scholar
• Wang SS, Chu CJ, Lee FY, Wu SL, Lin HC, Chan CC, et al. Effects of prostacyclin inhibition on splanchnic hyposensitivity to glypressin in a hemorrhage-transfused rat model of portal hypertension. Scand J Gastroenterol 2000; 35: 426–32
   PubMed Web of Science ®Google Scholar
• Lee FY, Wang SS, Tsai YT, Lin HJ, Lin HC, Chu CJ, et al. Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats. J Hepatol 1997; 26: 687–93
   PubMed Web of Science ®Google Scholar
• Wang SS, Chan CC, Lee FY, Chang FY, Lin HC, Chen CT, et al. Effects of long-term octreotide treatment on the response of portal-systemic collaterals to vasopressin in portal hypertensive rats. Eur J Clin Invest 2002; 32: 316–21
   PubMedGoogle Scholar
• Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of Nω-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993; 105: 1464–70
   PubMed Web of Science ®Google Scholar
• Huang HC, Wang SS, Chan CC, Lee FY, Chang FY, Lin HC, et al. Chronic inhibition of nitric oxide increases the collateral vascular responsiveness to vasopressin in portal hypertensive rats. J Hepatol 2004; 40: 234–8
   PubMedGoogle Scholar
• Chojkier M, Groszmann RJ. Measurement of the portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981; 240: G371–5
   PubMed Web of Science ®Google Scholar
• Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of the endothelium. Am J Physiol 1992; 263: G544–50
   PubMedGoogle Scholar
• Hamilton RL, Berry MN, Williams MC, Severinghaus EM. A simple and inexpensive membrane “lung” for small organ perfusions. J Lipid Res 1974; 15: 182–6
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Mackenzie ET, McCulloch J. Prostaglandins and other eicosanoids. Cerebral blood flow and metabolism. Raven Press, New York 1993; 339–77
   Google Scholar
• Blanchart A, Hernando N, Fernandez-Munoz D, Hernando L, Lopez-Novoa JM. Lack of effect of indomethacin on systemic and splanchnic haemodynamics in portal hypertensive rats. Clin Sci 1985; 68: 605–7
   Google Scholar
• Suzuki S, Franco Saenz R, Tan SY, Mulron PJ. Effects of indomethacin on plasma renin activity in the conscious rat. Am J Physiol 1981; 240: E286–9
   PubMedGoogle Scholar
• Fernandez M, Garcia-Pagan JC, Casadevall M, Mourelle MI, Pique JM, Bosch J, et al. Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis. Gastroenterology 1996; 110: 1529–35
   PubMed Web of Science ®Google Scholar
• Sitzmann JV, Bulkley GB, Mitchell MC, Campbell K. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann Surg 1989; 209: 322–7
   PubMed Web of Science ®Google Scholar
• da Cunha V, Rossoni LV, Oliveira PA, Poton S, Pretti SC, Vassallo DV, et al. Cyclooxygenase inhibition reduces blood pressure elevation and vascular reactivity dysfunction caused by inhibition of nitric oxide synthase in rats. Clin Exp Hypertens 2000; 22: 203–15
   PubMed Web of Science ®Google Scholar
• Tetsuka T, Daphna-Iken D, Srivastava SK, Baier LD, DuMaine J, Morrison AR. Cross-talk between cyclooxygenase and nitric oxide pathways: prostaglandin E2 negatively modulates induction of nitric oxide synthase by interleukin 1. Proc Natl Acad Sci USA 1994; 91: 12168–72
   PubMed Web of Science ®Google Scholar
• Gorodetsky JS, HLA TT, Bailey JM. Recovery of prostacyclin synthesis in human vascular endothelial cells following intermittent or continuous exposure to indomethacin. Pharmacol Res Commun 1985; 17: 447–56
   PubMedGoogle Scholar
• Feigen LP, King LW, Ray J, Beckett W, Kadowitz PJ. Differential effects of ibuprofen and indomethacin in the regional circulation of the dog. J Pharmacol Exp Ther 1981; 219: 679–84
   PubMed Web of Science ®Google Scholar
• Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52–7
   PubMed Web of Science ®Google Scholar
• Sumanovski LT, Battegay E, Stumm M, Van Der Kooij M, Sieber CC. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology 1999; 29: 1044–9
   PubMed Web of Science ®Google Scholar
• Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol 2001; 34: 644–50
   PubMed Web of Science ®Google Scholar
• Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000; 130: 641–9
   PubMed Web of Science ®Google Scholar
• Silverman KJ, Lund DP, Zetter BR, Lainey LL, Shahood JA, Freiman DG, et al. Angiogenic activity of adipose tissue. Biochem Biophy Res Com 1988; 153: 347–52
   PubMed Web of Science ®Google Scholar